ATE359367T1 - Ldl-rezeptor - Google Patents

Ldl-rezeptor

Info

Publication number
ATE359367T1
ATE359367T1 AT98917374T AT98917374T ATE359367T1 AT E359367 T1 ATE359367 T1 AT E359367T1 AT 98917374 T AT98917374 T AT 98917374T AT 98917374 T AT98917374 T AT 98917374T AT E359367 T1 ATE359367 T1 AT E359367T1
Authority
AT
Austria
Prior art keywords
gene
diseases
methods
diabetes
nucleic acid
Prior art date
Application number
AT98917374T
Other languages
German (de)
English (en)
Inventor
John Andrew Todd
John Wilfred Hess
Charles Thomas Caskey
Roger David Cox
David Gerhold
Holly Hammond
Patricia Hey
Yoshihiko Kawaguchi
Tony Raymond Merriman
Michael Lee Metzker
Yusuke Nakagawa
Michael Sean Phillips
Rebecca Christina Joan Twells
Original Assignee
Wellcome Trust Ltd As Trustee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Trust Ltd As Trustee, Merck & Co Inc filed Critical Wellcome Trust Ltd As Trustee
Application granted granted Critical
Publication of ATE359367T1 publication Critical patent/ATE359367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
AT98917374T 1997-04-15 1998-04-15 Ldl-rezeptor ATE359367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4355397P 1997-04-15 1997-04-15
US4874097P 1997-06-05 1997-06-05

Publications (1)

Publication Number Publication Date
ATE359367T1 true ATE359367T1 (de) 2007-05-15

Family

ID=26720554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917374T ATE359367T1 (de) 1997-04-15 1998-04-15 Ldl-rezeptor

Country Status (9)

Country Link
US (1) US6545137B1 (https=)
EP (1) EP0988379B1 (https=)
JP (1) JP4271735B2 (https=)
AT (1) ATE359367T1 (https=)
AU (1) AU733722B2 (https=)
CA (1) CA2286313C (https=)
DE (1) DE69837542T2 (https=)
ES (1) ES2285767T3 (https=)
WO (1) WO1998046743A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244577B2 (en) * 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
FR2798138B1 (fr) * 1999-09-03 2004-05-21 Centre Nat Rech Scient Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
IL151904A0 (en) * 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3
CA2410253C (en) * 2000-05-26 2010-06-15 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
AU2001295010A1 (en) * 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
EP1434783A4 (en) * 2001-03-16 2006-06-07 Lilly Co Eli LP-mammalian proteins; RELATED REAGENTS
JP2004537289A (ja) 2001-05-11 2004-12-16 ゲノム　セラピューティックス　コーポレーション 骨量および脂質レベルを調整するｈｂｍ変異型
US20040221326A1 (en) * 2001-05-11 2004-11-04 Philip Babij Transgenic animal model of bone mass modulation
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
IL158750A0 (en) * 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
HK1079705A1 (zh) 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
GB2381790A (en) * 2001-09-26 2003-05-14 Glaxo Group Ltd LDL-receptor polypeptides
JP2005220022A (ja) * 2002-03-08 2005-08-18 Anges Mg Inc Ｗｎｔの新規作用、及び、疾患治療への応用
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
US20030219793A1 (en) * 2002-10-04 2003-11-27 Carulli John P. High bone mass gene of 11q13.3
WO2005049640A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
WO2005049797A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
WO2005048913A2 (en) * 2003-11-24 2005-06-02 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
PL3630816T3 (pl) 2017-05-31 2024-08-05 Boehringer Ingelheim International Gmbh Polipeptydy antagonizujące sygnalizację wnt w komórkach nowotworowych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU1173995A (en) * 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
WO1995030774A1 (en) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
JPH11508263A (ja) * 1995-06-23 1999-07-21 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ アグーチシグナルタンパク質およびそのペプチドの脱色活性
IL151904A0 (en) 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3

Also Published As

Publication number Publication date
JP4271735B2 (ja) 2009-06-03
CA2286313A1 (en) 1998-10-22
AU7061498A (en) 1998-11-11
DE69837542T2 (de) 2008-01-31
EP0988379B1 (en) 2007-04-11
EP0988379A1 (en) 2000-03-29
ES2285767T3 (es) 2007-11-16
CA2286313C (en) 2011-01-11
JP2002501376A (ja) 2002-01-15
DE69837542D1 (de) 2007-05-24
WO1998046743A1 (en) 1998-10-22
US6545137B1 (en) 2003-04-08
AU733722B2 (en) 2001-05-24

Similar Documents

Publication Publication Date Title
ATE359367T1 (de) Ldl-rezeptor
Zmuda et al. Recent progress in understanding the genetic susceptibility to osteoporosis.
Lambrechts et al. Conventional and microfilled composite resins. Part II. Chip fractures.
Srinivas et al. Oral lichen planus-Review on etiopathogenesis
Kim et al. Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis
EP0814158A3 (en) Human C3a receptor variant; uses in diagnostics and therapeutics
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
HUP9902327A2 (hu) Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk
Giurgea et al. TCF4 deletions in Pitt‐Hopkins syndrome
WO1999021991A1 (en) Bmzf12: a zinc finger gene cloned from bone marrow
Tyas Clinical evaluation of a polyacid-modified resin composite (compomer).
Ke et al. The regulation of self-tolerance and the role of inflammasome molecules
Sohn et al. Clinical, biochemical, and genetic analysis of two korean patients with trichorhinophalangeal syndrome type I and growth hormone deficiency
Carter et al. Factors influencing the retention of cemented implant-supported crowns.
Hufnagl et al. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice
KR970704887A (ko) 혈청 파라옥소나제
EP1556493A4 (en) NEW COMPLETE GENETIC DNA OF THE JAPANESE CEPHALITIS VIRUS, INFECTIOUS JEV CDNA FROM AND THEIR USE
US8075894B2 (en) Use of soluble CD164 in inflammatory and/or autoimmune disorders
WO1997044454A3 (en) Human phospholipase inhibitor
WO2000021983A3 (en) Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
Tyas Three-year clinical evaluation of a polyacid-modified resin composite (Dyract).
EP0693183A4 (en) METHOD FOR DETERMINING DIABETES SENSITIVITY IN ASYMPTOMATIC PATIENTS
Mansouri et al. The immunogenetics of lichen planus
Chassin et al. The human homolog of ribosomal protein S18
Liebers et al. Epitope mapping with peptides of Chi t I component III and immunomodulation of the Chi t immune response

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties